IOVANCE BIOTHERAPEUTICS, INC. Gain (Loss) on Termination of Lease
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Gain (Loss) on Termination of Lease of $5.57 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2026-02-24
- IOVANCE BIOTHERAPEUTICS, INC. gain (loss) on termination of lease for fiscal 2024 was $5.57M.
| Period end | Gain (Loss) on Termination of Lease 12 month |
|---|---|
| 2024-12-31 | $5.57M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |